SG10202110112TA - Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors - Google Patents
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitorsInfo
- Publication number
- SG10202110112TA SG10202110112TA SG10202110112TA SG10202110112TA SG 10202110112T A SG10202110112T A SG 10202110112TA SG 10202110112T A SG10202110112T A SG 10202110112TA SG 10202110112T A SG10202110112T A SG 10202110112TA
- Authority
- SG
- Singapore
- Prior art keywords
- quinoline derivatives
- lrrk2 inhibitors
- novel imidazo
- imidazo
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469756P | 2017-03-10 | 2017-03-10 | |
| US201862629152P | 2018-02-12 | 2018-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202110112TA true SG10202110112TA (en) | 2021-10-28 |
Family
ID=61683855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202110112T SG10202110112TA (en) | 2017-03-10 | 2018-03-06 | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| SG11201908322W SG11201908322WA (en) | 2017-03-10 | 2018-03-06 | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908322W SG11201908322WA (en) | 2017-03-10 | 2018-03-06 | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11312713B2 (en) |
| EP (1) | EP3592741B1 (en) |
| JP (1) | JP7219223B2 (en) |
| KR (1) | KR102582626B1 (en) |
| CN (1) | CN111051304B (en) |
| AU (1) | AU2018230236B2 (en) |
| BR (1) | BR112019018688A2 (en) |
| CA (1) | CA3056030A1 (en) |
| IL (1) | IL269214B (en) |
| MX (1) | MX2019010756A (en) |
| SG (2) | SG10202110112TA (en) |
| TW (1) | TWI701246B (en) |
| WO (1) | WO2018163066A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230357269A1 (en) | 2020-05-06 | 2023-11-09 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
| JP2024512449A (en) | 2021-03-18 | 2024-03-19 | レ ラボラトワール セルヴィエ | Macrocyclic LRRK2 kinase inhibitor |
| WO2023220247A1 (en) * | 2022-05-12 | 2023-11-16 | Interline Therapeutics, Inc. | Lrrk2 inhibitors |
| WO2023220238A1 (en) * | 2022-05-12 | 2023-11-16 | Interline Therapeutics, Inc. | Lrrk2 inhibitors |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| DE3438830A1 (en) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | PHARMACEUTICAL FORM CONTAINING NIFEDIPIN AND METHOD FOR THE PRODUCTION THEREOF |
| CA1335996C (en) * | 1988-02-16 | 1995-06-20 | Susumu Takada | 2-substituted carbonylimidazo¬4,5-c|quinolines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| EP0580860B2 (en) | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (en) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | Oral pharmaceutical composition |
| DE69432629T3 (en) | 1993-01-25 | 2008-01-17 | Takeda Pharmaceutical Co. Ltd. | ANTIBODIES AGAINST BETA AMYLOID OR DERIVATIVES AND ITS USE |
| DE19504832A1 (en) | 1995-02-14 | 1996-08-22 | Basf Ag | Solid drug preparations |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| ATE402717T1 (en) | 1997-04-09 | 2008-08-15 | Intellect Neurosciences Inc | RECOMBINANT ANTIBODIES SPECIFIC TO BETA-AMYLOID TERMS, DNA CODING THEREFOR, AND METHOD FOR USE THEREOF |
| DK0901786T3 (en) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Solid pharmaceutical dispersions with increased bioavailability |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TR200202799T3 (en) | 2000-02-24 | 2003-03-21 | Washington University St.Louis | Humanized antibodies that sequence the AB peptide |
| JP4708675B2 (en) | 2000-11-03 | 2011-06-22 | プロテオテック・インコーポレーテッド | Method for isolating amyloid inhibitory compounds from Uncaria tomentosa and related plants and use of the isolated compounds |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (en) | 2002-08-23 | 2004-03-04 | Bayer Ag | New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance |
| DE10238723A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl substituted pyrazolyprimidines |
| CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| CA2528652A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| MY157827A (en) | 2003-06-27 | 2016-07-29 | 3M Innovative Properties Co | Sulfonamide substituted imidazoquinolines |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| AR046845A1 (en) * | 2003-11-21 | 2005-12-28 | Novartis Ag | DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES |
| WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| EA016357B1 (en) | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Antibodies directed against amyloid-beta peptide and methods using same |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| DE602006018301D1 (en) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | HISTAMINE-3 RECEPTOR ANTAGONISTS |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| WO2007052124A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| JP2009539762A (en) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Tetralin antagonist of H3 receptor |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| AU2008208653B2 (en) | 2007-01-22 | 2012-11-22 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| ITMI20070890A1 (en) | 2007-05-04 | 2008-11-05 | Sifi Spa | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| EP2571877B1 (en) | 2010-05-17 | 2018-08-15 | Boehringer Ingelheim International GmbH | 1h-imidazo[4,5-c]quinolines |
| ES2524892T3 (en) | 2010-09-02 | 2014-12-15 | Glaxosmithkline Intellectual Property Development Limited | 2- (Benzyloxy) benzamides as inhibitors of LRRK2 kinase |
| US9233977B2 (en) | 2010-10-29 | 2016-01-12 | Merck Sharp & Dohme Corp. | Leucine-rich repeat kinase enzyme activity |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| EP2903989A1 (en) | 2012-10-04 | 2015-08-12 | Pfizer Limited | Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors |
| WO2014060113A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Novel kinase inhibitors |
| ITTO20130694A1 (en) | 2013-08-14 | 2015-02-15 | Umbra Meccanotecnica | WASHPIPE JOINT FOR A PETROLIFY DRILLING SYSTEM |
| UA115388C2 (en) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders |
| WO2016009297A1 (en) | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
| WO2016108130A1 (en) | 2014-12-30 | 2016-07-07 | Sun Pharmaceutical Industries Limited | Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds |
| AU2016322813B2 (en) * | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
| US20170348285A1 (en) | 2016-06-01 | 2017-12-07 | Harold Richard Hellstrom | Treatment of dry eye disease with parasympathetic & anti-sympathetic agents |
| IL269215B (en) * | 2017-03-10 | 2022-09-01 | Pfizer | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
-
2018
- 2018-03-06 MX MX2019010756A patent/MX2019010756A/en unknown
- 2018-03-06 KR KR1020197029735A patent/KR102582626B1/en active IP Right Grant
- 2018-03-06 SG SG10202110112T patent/SG10202110112TA/en unknown
- 2018-03-06 CN CN201880029989.5A patent/CN111051304B/en active Active
- 2018-03-06 US US16/492,558 patent/US11312713B2/en active Active
- 2018-03-06 CA CA3056030A patent/CA3056030A1/en active Pending
- 2018-03-06 AU AU2018230236A patent/AU2018230236B2/en active Active
- 2018-03-06 BR BR112019018688A patent/BR112019018688A2/en unknown
- 2018-03-06 SG SG11201908322W patent/SG11201908322WA/en unknown
- 2018-03-06 WO PCT/IB2018/051439 patent/WO2018163066A1/en active Application Filing
- 2018-03-06 EP EP18711703.1A patent/EP3592741B1/en active Active
- 2018-03-06 JP JP2019549462A patent/JP7219223B2/en active Active
- 2018-03-07 TW TW107107734A patent/TWI701246B/en active
-
2019
- 2019-09-09 IL IL269214A patent/IL269214B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019131727A3 (en) | 2021-04-26 |
| IL269214B (en) | 2022-03-01 |
| US11312713B2 (en) | 2022-04-26 |
| RU2019131727A (en) | 2021-04-12 |
| AU2018230236A1 (en) | 2019-10-31 |
| SG11201908322WA (en) | 2019-10-30 |
| JP2020510046A (en) | 2020-04-02 |
| KR102582626B1 (en) | 2023-09-22 |
| MX2019010756A (en) | 2020-01-20 |
| KR20190138793A (en) | 2019-12-16 |
| CA3056030A1 (en) | 2018-09-13 |
| CN111051304B (en) | 2022-12-27 |
| JP7219223B2 (en) | 2023-02-07 |
| WO2018163066A1 (en) | 2018-09-13 |
| BR112019018688A2 (en) | 2020-04-07 |
| AU2018230236B2 (en) | 2022-05-19 |
| EP3592741A1 (en) | 2020-01-15 |
| EP3592741B1 (en) | 2023-02-15 |
| TWI701246B (en) | 2020-08-11 |
| CN111051304A (en) | 2020-04-21 |
| TW201900642A (en) | 2019-01-01 |
| US20210355117A1 (en) | 2021-11-18 |
| IL269214A (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258857A1 (en) | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors | |
| HK1258905A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| EP3280715A4 (en) | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | |
| PT3712152T (en) | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors | |
| PL3371185T3 (en) | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors | |
| IL251164A0 (en) | Imidazo[4,5-c]pyridine derived ssao inhibitors | |
| EP3154970A4 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| IL269214B (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| IL290419B (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| HK1255804A1 (en) | New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors | |
| IL272988A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| IL251166A0 (en) | Imidazo[4,5-c]pyridine derived ssao inhibitors | |
| EP3302060A4 (en) | Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase | |
| IL269215A (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives |